CN104812387A - 取代的1,6-萘啶 - Google Patents

取代的1,6-萘啶 Download PDF

Info

Publication number
CN104812387A
CN104812387A CN201380060294.0A CN201380060294A CN104812387A CN 104812387 A CN104812387 A CN 104812387A CN 201380060294 A CN201380060294 A CN 201380060294A CN 104812387 A CN104812387 A CN 104812387A
Authority
CN
China
Prior art keywords
naphthyridine
carboxamide
chlorophenyl
phenyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380060294.0A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙娜·M·切卡雷利
拉维·姚高希亚
罗兰·雅各布-勒特
赖纳·E·马丁
延斯-乌韦·彼得斯
于尔根·维希曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104812387A publication Critical patent/CN104812387A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CN201380060294.0A 2012-11-20 2013-11-18 取代的1,6-萘啶 Pending CN104812387A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12193311.3 2012-11-20
EP12193311 2012-11-20
PCT/EP2013/074012 WO2014079787A1 (en) 2012-11-20 2013-11-18 Substituted 1,6-naphthyridines

Publications (1)

Publication Number Publication Date
CN104812387A true CN104812387A (zh) 2015-07-29

Family

ID=47189816

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380060294.0A Pending CN104812387A (zh) 2012-11-20 2013-11-18 取代的1,6-萘啶

Country Status (13)

Country Link
US (1) US9657014B2 (enExample)
EP (1) EP2922540A1 (enExample)
JP (1) JP2016505534A (enExample)
KR (1) KR20150085538A (enExample)
CN (1) CN104812387A (enExample)
AR (1) AR093519A1 (enExample)
BR (1) BR112015011094A2 (enExample)
CA (1) CA2890685A1 (enExample)
HK (1) HK1207317A1 (enExample)
MX (1) MX2015006364A (enExample)
RU (1) RU2015120217A (enExample)
TW (1) TW201425312A (enExample)
WO (1) WO2014079787A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI529171B (zh) 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
WO2016009076A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
CA2974874A1 (en) * 2015-02-11 2016-08-18 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
SG11201706869XA (en) 2015-03-24 2017-09-28 Shanghai Yingli Pharm Co Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
EP3371164B1 (en) * 2015-11-06 2022-03-16 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
MX2021008152A (es) 2019-01-03 2021-10-13 Univ Pittsburgh Commonwealth Sys Higher Education Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb.
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
AU2021401429A1 (en) * 2020-12-18 2023-07-06 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030584A1 (en) * 2004-08-03 2006-02-09 Hanson Gunnar J 2,8-Disubstituted naphthyridine derivatives
WO2010101949A1 (en) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
EP2380878A1 (en) * 2009-01-19 2011-10-26 Daiichi Sankyo Company, Limited Cyclic compound having hetero atom
EP2418203A1 (en) * 2009-04-06 2012-02-15 Daiichi Sankyo Company, Limited Cyclic compound having substituted phenyl group

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
US6255318B1 (en) * 1997-12-11 2001-07-03 Biochem Pharma Inc. Antiviral compounds
AU2002218902A1 (en) 2000-12-27 2002-07-08 Shire Biochem Inc. Macrocyclic anti-viral compounds
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
JP2012036168A (ja) 2010-07-15 2012-02-23 Daiichi Sankyo Co Ltd ヘテロ原子を有する環状化合物を含有する医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030584A1 (en) * 2004-08-03 2006-02-09 Hanson Gunnar J 2,8-Disubstituted naphthyridine derivatives
EP2380878A1 (en) * 2009-01-19 2011-10-26 Daiichi Sankyo Company, Limited Cyclic compound having hetero atom
WO2010101949A1 (en) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
EP2418203A1 (en) * 2009-04-06 2012-02-15 Daiichi Sankyo Company, Limited Cyclic compound having substituted phenyl group

Also Published As

Publication number Publication date
TW201425312A (zh) 2014-07-01
EP2922540A1 (en) 2015-09-30
KR20150085538A (ko) 2015-07-23
BR112015011094A2 (pt) 2017-07-11
US20150252044A1 (en) 2015-09-10
JP2016505534A (ja) 2016-02-25
WO2014079787A1 (en) 2014-05-30
CA2890685A1 (en) 2014-05-30
US9657014B2 (en) 2017-05-23
MX2015006364A (es) 2015-10-05
HK1207317A1 (en) 2016-01-29
RU2015120217A (ru) 2017-01-10
AR093519A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
CN104812387A (zh) 取代的1,6-萘啶
CN107295798B (zh) 苯并氮杂*二甲酰胺化合物
TWI664164B (zh) 作為ｌｓｄ１抑制劑之環丙胺
RU2677667C2 (ru) Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
CN100463908C (zh) 取代的8’-吡啶基-二氢螺-[环烷基]-嘧啶并[1,2-a]嘧啶-6-酮和8’-嘧啶基-二氢螺-[环烷基]-嘧啶并[1,2-a]嘧啶-6-酮衍生物
CN115850268A (zh) 作为cftr增效剂的吡咯并嘧啶
CN105163727B (zh) 刺激神经发生的异喹啉衍生物
CN108349981A (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
CN102482218A (zh) 作为蛋白激酶调节剂的吡啶和吡嗪衍生物
CN115667216A (zh) 用于治疗癌症的作为tead蛋白和hippo-yap1/taz信号传导级联抑制剂的(1h-吲哚-5-基)丙烯酰胺衍生物
CN108834412A (zh) 嘧啶及其变体、及其用途
CN108026050A (zh) 作为RORγ调节剂的新型化合物
CN105473568B (zh) 1,7‑萘啶衍生物
CN106459071A (zh) 新的三环醌衍生物
CN113924092A (zh) 喹啉和喹唑啉化合物以及其使用方法
CN104093712A (zh) 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物
CN113968856B (zh) 一类具有激酶抑制活性的化合物
CN110818641A (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN105764901B (zh) 作为用于治疗神经变性疾病的神经源性药的吡啶并[4，3-b]吡嗪-2-甲酰胺
CN100376576C (zh) 取代的2-(二氮杂-双环-烷基)-嘧啶酮衍生物
CN105246895B (zh) 哌嗪并[1，2‑a]吲哚‑1‑酮和[1，4]二氮杂环庚烷并[1，2‑a]吲哚‑1‑酮
CN114269736A (zh) 一种酰胺化合物、药物组合物及其应用
CN114181205B (zh) 吡唑并吡啶类化合物或其盐及其制备方法和用途
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
WO2021147699A1 (zh) 吡啶并杂环类化合物、其制备方法及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207317

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150729

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1207317

Country of ref document: HK